Group 1 - The stock price of Fujilai as of August 11, 2025, closed at 37.44 yuan, down 0.58% from the previous trading day [1] - The trading volume on that day was 47,322 lots, with a transaction amount of 176 million yuan [1] - Fujilai's main business includes the research, production, and sales of pharmaceutical intermediates, active pharmaceutical ingredients, and formulations, primarily used in oncology, antiviral, and cardiovascular fields [1] Group 2 - As of July 31, 2025, the total number of shareholders for Fujilai was 13,377 [1] - The company is currently implementing a share repurchase plan, with further details to be announced in subsequent announcements [1] - On August 11, 2025, the net inflow of main funds was 2.2474 million yuan, with a cumulative net inflow of 31.5657 million yuan over the past five days [1]

Group 1 - The stock price of Tianyu Co., Ltd. closed at 25.65 yuan on August 5, 2025, down by 0.15 yuan, a decrease of 0.58% from the previous trading day [1] - The trading volume on that day was 35,396 hands, with a transaction amount of 0.91 billion yuan, and a fluctuation of 2.17% [1] - Tianyu Co., Ltd. operates in the chemical pharmaceutical industry, focusing on the research, production, and sales of pharmaceutical intermediates, active pharmaceutical ingredients, and formulations [1] Group 2 - The company’s products cover multiple therapeutic areas, including antihypertensive, antihyperlipidemic, and antidiabetic treatments [1] - For the first half of 2025, the company expects a net profit attributable to shareholders of 1.3 billion to 1.8 billion yuan, representing a year-on-year growth of 144.29% to 238.25% [1] - On August 5, 2025, the net outflow of main funds was 5.96 million yuan, accounting for 0.11% of the circulating market value [1]